TW200500346A - HIV replication inhibiting indane substituted pyrimidines - Google Patents

HIV replication inhibiting indane substituted pyrimidines

Info

Publication number: TW200500346A
Authority: TW; Taiwan
Prior art keywords: hiv replication; substituted pyrimidines; replication inhibiting; indane; indane substituted
Prior art date: 2003-02-20

Application number

TW093104173A

Other languages

English (en)

Inventor

Jerome Emile Georges Guillemont

Elisabeth Therese Jeanne Pasquier

Jan Heeres

Kurt Hertogs

Eva Bettens

Paulus Joannes Lewi

Jonge Marc Rene De

Lucien Maria Henricus Koymans

Frederik Frans Desire Daeyaert

Hendrik Maarten Vinkers

Paul Adriaan Jan Janssen

Original Assignee

Tibotec Pharm Ltd

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2003-02-20

Filing date

2004-02-20

Publication date

2005-01-01

2004-02-20 Application filed by Tibotec Pharm Ltd filed Critical Tibotec Pharm Ltd

2005-01-01 Publication of TW200500346A publication Critical patent/TW200500346A/zh

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
- C07D239/47—One nitrogen atom and one oxygen or sulfur atom, e.g. cytosine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
- C07D239/48—Two nitrogen atoms
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Veterinary Medicine (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
Virology (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Communicable Diseases (AREA)
Oncology (AREA)
Molecular Biology (AREA)
Epidemiology (AREA)
AIDS & HIV (AREA)
Tropical Medicine & Parasitology (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Plural Heterocyclic Compounds (AREA)
Nitrogen Condensed Heterocyclic Rings (AREA)

TW093104173A 2003-02-20 2004-02-20 HIV replication inhibiting indane substituted pyrimidines TW200500346A (en)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
EP03100411		2003-02-20
US47501203P	2003-06-02	2003-06-02

Publications (1)

Publication Number	Publication Date
TW200500346A true TW200500346A (en)	2005-01-01

Family

ID=32910137

Family Applications (2)

Application Number	Title	Priority Date	Filing Date
TW093104173A TW200500346A (en)	2003-02-20	2004-02-20	HIV replication inhibiting indane substituted pyrimidines
TW093104175A TW200510339A (en)	2003-02-20	2004-02-20	HIV replication inhibiting pyrimidines and triazines

Family Applications After (1)

Application Number	Title	Priority Date	Filing Date
TW093104175A TW200510339A (en)	2003-02-20	2004-02-20	HIV replication inhibiting pyrimidines and triazines

Country Status (27)

Country	Link
US (2)	US7442705B2 (zh)
EP (2)	EP1603887B1 (zh)
JP (2)	JP4586014B2 (zh)
KR (2)	KR20050094896A (zh)
CN (2)	CN100572364C (zh)
AP (1)	AP2005003373A0 (zh)
AR (2)	AR044499A1 (zh)
AT (2)	ATE361915T1 (zh)
AU (2)	AU2004213187B2 (zh)
BR (2)	BRPI0407732A (zh)
CA (2)	CA2516699C (zh)
CL (2)	CL2004000303A1 (zh)
CY (1)	CY1106788T1 (zh)
DE (2)	DE602004032321D1 (zh)
DK (1)	DK1597238T3 (zh)
EA (2)	EA010423B1 (zh)
ES (1)	ES2287734T3 (zh)
HR (2)	HRP20050820A2 (zh)
IL (2)	IL169596A (zh)
MX (2)	MXPA05008866A (zh)
MY (1)	MY138308A (zh)
NO (2)	NO20054312L (zh)
NZ (2)	NZ541601A (zh)
PL (2)	PL226954B1 (zh)
PT (1)	PT1597238E (zh)
TW (2)	TW200500346A (zh)
WO (2)	WO2004074262A1 (zh)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
TWI329105B (en)	2002-02-01	2010-08-21	Rigel Pharmaceuticals Inc	2,4-pyrimidinediamine compounds and their uses
NZ537752A (en)	2002-07-29	2006-12-22	Rigel Pharmaceuticals Inc	Use of 2,4-pyrimidinediamine compounds in the preparation of medicaments for treating autoimmune diseases
CL2004000303A1 (es) *	2003-02-20	2005-04-08	Tibotec Pharm Ltd	Compuestos derivados de pirimidinas y triazinas; proceso de preparacion; composicion farmaceutica; y su uso para inhibir la replicacion del vih.
JP4886511B2 (ja)	2003-07-30	2012-02-29	ライジェルファーマシューティカルズ，インコーポレイテッド	２，４−ピリミジンジアミン化合物による自己免疫疾患の治療または予防方法
AU2005231507B2 (en)	2004-04-08	2012-03-01	Targegen, Inc.	Benzotriazine inhibitors of kinases
EP1799656A4 (en)	2004-08-25	2009-09-02	Targegen Inc	HETEROCYCLIC COMPOUNDS AND METHODS OF USE
DK1814878T3 (da)	2004-11-24	2012-05-07	Rigel Pharmaceuticals Inc	Spiro-2, 4-pyrimidindiamin-forbindelser og anvendelser deraf
KR101278397B1 (ko)	2005-01-19	2013-06-25	리겔 파마슈티칼스, 인크.	2,4-피리미딘디아민 화합물의 전구약물 및 이의 용도
US20070203161A1 (en)	2006-02-24	2007-08-30	Rigel Pharmaceuticals, Inc.	Compositions and methods for inhibition of the jak pathway
SG137989A1 (en)	2005-06-08	2008-01-28	Rigel Pharmaceuticals Inc	Compositions and methods for inhibition of the JAK pathway
US8133900B2 (en)	2005-11-01	2012-03-13	Targegen, Inc.	Use of bi-aryl meta-pyrimidine inhibitors of kinases
HUE028987T2 (en)	2005-11-01	2017-01-30	Targegen Inc	Bi-aryl meta-pyrimidine inhibitors of kinases
US8604042B2 (en)	2005-11-01	2013-12-10	Targegen, Inc.	Bi-aryl meta-pyrimidine inhibitors of kinases
JP2009528295A (ja)	2006-02-24	2009-08-06	ライジェルファーマシューティカルズ，インコーポレイテッド	Ｊａｋ経路の阻害のための組成物および方法
BRPI0722079B8 (pt) *	2006-12-29	2021-05-25	Janssen R & D Ireland	pirimidinas 5,6-substituídas inibidoras de hiv e composição farmacêutica que as compreende
JP5185283B2 (ja) *	2006-12-29	2013-04-17	テイボテク・フアーマシユーチカルズ	Ｈｉｖ阻害６−置換ピリミジン
US9273077B2 (en)	2008-05-21	2016-03-01	Ariad Pharmaceuticals, Inc.	Phosphorus derivatives as kinase inhibitors
EA029131B1 (ru)	2008-05-21	2018-02-28	Ариад Фармасьютикалз, Инк.	Фосфорсодержащие производные в качестве ингибиторов киназы
TW201008933A (en) *	2008-08-29	2010-03-01	Hutchison Medipharma Entpr Ltd	Pyrimidine compounds
AP2011005613A0 (en)	2008-09-11	2011-04-30	Pfizer	Heteroaryls amide derivatives and their use as glucokinase activators.
AR074210A1 (es) *	2008-11-24	2010-12-29	Boehringer Ingelheim Int	Derivados de pirimidina como inhibidores de ptk2-quinasa
TW201024281A (en)	2008-11-24	2010-07-01	Boehringer Ingelheim Int	New compounds
UA99882C2 (uk)	2009-03-11	2012-10-10	Пфайзер Інк.	Похідні бензофуранілу, фармацевтична композиція та спосіб лікування захворювань (варіанти)
WO2012060847A1 (en)	2010-11-07	2012-05-10	Targegen, Inc.	Compositions and methods for treating myelofibrosis
US9249124B2 (en)	2011-03-30	2016-02-02	H. Lee Moffitt Cancer Center And Research Institute, Inc.	Aurora kinase inhibitors and methods of making and using thereof
CA2832504C (en)	2011-05-04	2019-10-01	Ariad Pharmaceuticals, Inc.	Compounds for inhibiting cell proliferation in egfr-driven cancers
GB201119358D0 (en)	2011-11-10	2011-12-21	Lewi Paulus J	Disubstituted triazine dimers for treatment and/or prevention of infectious diseases
GB201204756D0 (en)	2012-03-19	2012-05-02	Lewi Paulus J	Triazines with suitable spacers for treatment and/or prevention of HIV infections
AU2013204563B2 (en)	2012-05-05	2016-05-19	Takeda Pharmaceutical Company Limited	Compounds for inhibiting cell proliferation in EGFR-driven cancers
WO2014072419A1 (en)	2012-11-08	2014-05-15	Universiteit Antwerpen	Novel anti-hiv compounds
US9611283B1 (en)	2013-04-10	2017-04-04	Ariad Pharmaceuticals, Inc.	Methods for inhibiting cell proliferation in ALK-driven cancers
CN108602802B (zh)	2016-07-26	2020-01-21	深圳市塔吉瑞生物医药有限公司	用于抑制蛋白酪氨酸激酶活性的氨基嘧啶类化合物
CN106749203B (zh) *	2016-11-28	2020-04-10	洛阳聚慧医药科技有限公司	一种嘧啶类杂环化合物、嘧啶类杂环化合物盐以及制备方法和应用
CN114127057B (zh)	2019-05-10	2024-07-12	德西费拉制药有限责任公司	苯基氨基嘧啶酰胺自噬抑制剂及其使用方法
EP4295846A3 (en)	2019-05-10	2024-02-28	Deciphera Pharmaceuticals, LLC	Heteroarylaminopyrimidine amide autophagy inhibitors and methods of use thereof
US11590134B2 (en)	2019-06-17	2023-02-28	Deciphera Pharmaceuticals, Llc	Aminopyrimidine amide autophagy inhibitors and methods of use thereof

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US3459731A (en)	1966-12-16	1969-08-05	Corn Products Co	Cyclodextrin polyethers and their production
US5691364A (en)	1995-03-10	1997-11-25	Berlex Laboratories, Inc.	Benzamidine derivatives and their use as anti-coagulants
PL189122B1 (pl)	1995-11-23	2005-06-30	Janssen Pharmaceutica Nv	Sposób wytwarzania mieszaniny stałej zawierającejjedną lub wiele cyklodekstryn, mieszanina stała ikompozycja farmaceutyczna
NO311614B1 (no) *	1996-10-01	2001-12-17	Janssen Pharmaceutica Nv	Substituerte diamino-1,3,5-triazinderivater
GB9705361D0 (en)	1997-03-14	1997-04-30	Celltech Therapeutics Ltd	Chemical compounds
EP0945447A1 (en) *	1998-03-27	1999-09-29	Janssen Pharmaceutica N.V.	Trisubstituted 1,3,5-triazine derivatives for treatment of HIV infections
ATE232521T1 (de)	1998-03-27	2003-02-15	Janssen Pharmaceutica Nv	Hiv hemmende pyrimidin derivate
EA004049B1 (ru) *	1998-11-10	2003-12-25	Янссен Фармацевтика Н.В.	Пиримидины, ингибирующие репликацию вич
GB9828511D0 (en) *	1998-12-24	1999-02-17	Zeneca Ltd	Chemical compounds
ES2391550T3 (es)	1999-04-15	2012-11-27	Bristol-Myers Squibb Company	Inhibidores cíclicos de la proteína tirosina quinasa
GB9914258D0 (en)	1999-06-18	1999-08-18	Celltech Therapeutics Ltd	Chemical compounds
KR100785360B1 (ko) *	1999-09-24	2007-12-18	얀센 파마슈티카 엔.브이.	항바이러스 조성물
AU770600B2 (en) *	1999-10-07	2004-02-26	Amgen, Inc.	Triazine kinase inhibitors
CA2406562C (en)	2000-05-08	2009-09-15	Janssen Pharmaceutica N.V.	Hiv replication inhibiting pyrimidines and triazines
WO2002036578A2 (en)	2000-10-31	2002-05-10	Lynn Bonham	Triazine derivatives as lpaat-b inhibitors and uses thereof
JO3429B1 (ar)	2001-08-13	2019-10-20	Janssen Pharmaceutica Nv	مشتقات برميدينات مثبطة فيروس الايدز
TWI329105B (en) *	2002-02-01	2010-08-21	Rigel Pharmaceuticals Inc	2,4-pyrimidinediamine compounds and their uses
ATE511858T1 (de) *	2002-02-05	2011-06-15	Astellas Pharma Inc	2,4,6-triamino-1,3,5-triazin-derivat
AR039540A1 (es) *	2002-05-13	2005-02-23	Tibotec Pharm Ltd	Compuestos microbicidas con contenido de pirimidina o triazina
AU2003244098A1 (en) *	2002-06-28	2004-01-19	Yamanouchi Pharmaceutical Co., Ltd.	Diaminopyrimidinecarboxa mide derivative
NZ537752A (en) *	2002-07-29	2006-12-22	Rigel Pharmaceuticals Inc	Use of 2,4-pyrimidinediamine compounds in the preparation of medicaments for treating autoimmune diseases
CL2004000303A1 (es) *	2003-02-20	2005-04-08	Tibotec Pharm Ltd	Compuestos derivados de pirimidinas y triazinas; proceso de preparacion; composicion farmaceutica; y su uso para inhibir la replicacion del vih.

2004
- 2004-02-19 CL CL200400303A patent/CL2004000303A1/es unknown
- 2004-02-19 CL CL200400306A patent/CL2004000306A1/es unknown
- 2004-02-20 BR BRPI0407732-6A patent/BRPI0407732A/pt not_active Application Discontinuation
- 2004-02-20 AR ARP040100548A patent/AR044499A1/es not_active Application Discontinuation
- 2004-02-20 EA EA200501326A patent/EA010423B1/ru not_active IP Right Cessation
- 2004-02-20 EA EA200501327A patent/EA011256B1/ru not_active IP Right Cessation
- 2004-02-20 AP AP2005003373A patent/AP2005003373A0/xx unknown
- 2004-02-20 AU AU2004213187A patent/AU2004213187B2/en not_active Ceased
- 2004-02-20 CN CNB2004800043162A patent/CN100572364C/zh not_active Expired - Fee Related
- 2004-02-20 MX MXPA05008866A patent/MXPA05008866A/es active IP Right Grant
- 2004-02-20 HR HR20050820A patent/HRP20050820A2/xx not_active Application Discontinuation
- 2004-02-20 AT AT04737252T patent/ATE361915T1/de not_active IP Right Cessation
- 2004-02-20 CA CA2516699A patent/CA2516699C/en not_active Expired - Fee Related
- 2004-02-20 EP EP04737251A patent/EP1603887B1/en not_active Expired - Lifetime
- 2004-02-20 NZ NZ541601A patent/NZ541601A/en unknown
- 2004-02-20 US US10/545,358 patent/US7442705B2/en not_active Expired - Lifetime
- 2004-02-20 AU AU2004213186A patent/AU2004213186B2/en not_active Ceased
- 2004-02-20 KR KR1020057014231A patent/KR20050094896A/ko not_active Ceased
- 2004-02-20 US US10/545,719 patent/US7585870B2/en not_active Expired - Lifetime
- 2004-02-20 WO PCT/EP2004/050177 patent/WO2004074262A1/en not_active Ceased
- 2004-02-20 DK DK04737252T patent/DK1597238T3/da active
- 2004-02-20 MY MYPI20040575A patent/MY138308A/en unknown
- 2004-02-20 PT PT04737252T patent/PT1597238E/pt unknown
- 2004-02-20 BR BRPI0407741A patent/BRPI0407741B8/pt not_active IP Right Cessation
- 2004-02-20 PL PL378064A patent/PL226954B1/pl unknown
- 2004-02-20 JP JP2006502042A patent/JP4586014B2/ja not_active Expired - Fee Related
- 2004-02-20 CN CN2004800043209A patent/CN1751031B/zh not_active Expired - Fee Related
- 2004-02-20 EP EP04737252A patent/EP1597238B1/en not_active Expired - Lifetime
- 2004-02-20 DE DE602004032321T patent/DE602004032321D1/de not_active Expired - Lifetime
- 2004-02-20 NZ NZ542428A patent/NZ542428A/en unknown
- 2004-02-20 HR HR20050821A patent/HRP20050821A2/xx not_active Application Discontinuation
- 2004-02-20 AT AT04737251T patent/ATE506353T1/de not_active IP Right Cessation
- 2004-02-20 KR KR1020057014648A patent/KR20050099994A/ko not_active Ceased
- 2004-02-20 TW TW093104173A patent/TW200500346A/zh unknown
- 2004-02-20 TW TW093104175A patent/TW200510339A/zh unknown
- 2004-02-20 JP JP2006502041A patent/JP4586013B2/ja not_active Expired - Fee Related
- 2004-02-20 CA CA2516589A patent/CA2516589C/en not_active Expired - Fee Related
- 2004-02-20 WO PCT/EP2004/050175 patent/WO2004074261A1/en not_active Ceased
- 2004-02-20 AR ARP040100549A patent/AR044500A1/es not_active Application Discontinuation
- 2004-02-20 MX MXPA05008867A patent/MXPA05008867A/es active IP Right Grant
- 2004-02-20 DE DE602004006383T patent/DE602004006383T2/de not_active Expired - Lifetime
- 2004-02-20 PL PL378136A patent/PL227295B1/pl unknown
- 2004-02-20 ES ES04737252T patent/ES2287734T3/es not_active Expired - Lifetime
2005
- 2005-07-07 IL IL169596A patent/IL169596A/en active IP Right Grant
- 2005-07-12 IL IL169647A patent/IL169647A/en active IP Right Grant
- 2005-09-19 NO NO20054312A patent/NO20054312L/no not_active Application Discontinuation
- 2005-09-19 NO NO20054311A patent/NO20054311L/no not_active Application Discontinuation
2007
- 2007-08-03 CY CY20071101039T patent/CY1106788T1/el unknown

Also Published As

Publication number	Publication date
EP1603887A1 (en)	2005-12-14
PL227295B1 (pl)	2017-11-30
ES2287734T3 (es)	2007-12-16
CN100572364C (zh)	2009-12-23
AU2004213186A1 (en)	2004-09-02
CA2516589A1 (en)	2004-09-02
EP1603887B1 (en)	2011-04-20
MY138308A (en)	2009-05-29
AU2004213187B2 (en)	2009-11-05
NO20054312D0 (no)	2005-09-19
CN1751031A (zh)	2006-03-22
DE602004032321D1 (de)	2011-06-01
EA011256B1 (ru)	2009-02-27
US7442705B2 (en)	2008-10-28
TW200510339A (en)	2005-03-16
DE602004006383T2 (de)	2008-01-10
EP1597238A1 (en)	2005-11-23
WO2004074262A1 (en)	2004-09-02
WO2004074261A1 (en)	2004-09-02
AR044499A1 (es)	2005-09-14
IL169596A0 (en)	2007-07-04
AR044500A1 (es)	2005-09-14
KR20050094896A (ko)	2005-09-28
NZ542428A (en)	2007-11-30
BRPI0407741B8 (pt)	2021-05-25
DK1597238T3 (da)	2007-09-10
IL169596A (en)	2017-02-28
IL169647A (en)	2013-05-30
CL2004000303A1 (es)	2005-04-08
BRPI0407732A (pt)	2006-02-14
EA010423B1 (ru)	2008-08-29
MXPA05008867A (es)	2005-10-05
CN1751031B (zh)	2010-07-21
BRPI0407741B1 (pt)	2018-05-29
CA2516699C (en)	2011-07-12
AU2004213186B2 (en)	2009-10-01
CY1106788T1 (el)	2012-05-23
AP2005003373A0 (en)	2005-09-30
PL378064A1 (pl)	2006-02-20
CA2516699A1 (en)	2004-09-02
HRP20050821A2 (en)	2006-11-30
JP2006518357A (ja)	2006-08-10
EA200501327A1 (ru)	2006-02-24
ATE361915T1 (de)	2007-06-15
NO20054311D0 (no)	2005-09-19
KR20050099994A (ko)	2005-10-17
ATE506353T1 (de)	2011-05-15
MXPA05008866A (es)	2005-10-05
NO20054311L (no)	2005-10-27
EA200501326A1 (ru)	2006-02-24
BRPI0407741A (pt)	2006-02-14
EP1597238B1 (en)	2007-05-09
PL226954B1 (pl)	2017-10-31
CN1751030A (zh)	2006-03-22
US20060194804A1 (en)	2006-08-31
IL169647A0 (en)	2007-07-04
JP2006518356A (ja)	2006-08-10
CA2516589C (en)	2012-04-17
NO20054312L (no)	2005-11-16
NZ541601A (en)	2007-09-28
AU2004213187A1 (en)	2004-09-02
JP4586013B2 (ja)	2010-11-24
PL378136A1 (pl)	2006-03-06
PT1597238E (pt)	2007-08-08
US20060142571A1 (en)	2006-06-29
DE602004006383D1 (de)	2007-06-21
HRP20050820A2 (en)	2006-11-30
US7585870B2 (en)	2009-09-08
JP4586014B2 (ja)	2010-11-24
CL2004000306A1 (es)	2005-04-08

Publication	Publication Date	Title
TW200500346A (en)	2005-01-01	HIV replication inhibiting indane substituted pyrimidines
WO2001085700A3 (en)	2002-02-07	Hiv replication inhibiting pyrimidines and triazines
SA520411990B1 (ar)	2022-07-24	مركبات مفيدة لتثبيط إنزيم كيناز 7 المعتمد على السيكلين
EA202192099A3 (ru)	2022-02-28	Системы доставки с замедленным высвобождением, содержащие бесследные линкеры
PH12022551226A1 (en)	2023-06-14	Pyrrolotriazine compounds acting as mnk inhibitor
SA520411524B1 (ar)	2024-03-14	مركبات تنشيط القسيم العضلي ثنائي الأميد واستخداماتها
MXPA05008368A (es)	2005-11-04	1,2,4-triazinas inhibidoras del virus de inmunodeficiencia humana.
UA83091C2 (en)	2008-06-10	Pyrido[2,3-d]pyrimidine-2,4-diamines as pde 2 inhibitors
TW200613243A (en)	2006-05-01	Novel compounds
TW200517106A (en)	2005-06-01	Sustained release pharmaceutical compositions
TW200639156A (en)	2006-11-16	New compounds
CA2437785A1 (en)	2002-10-10	Hiv inhibiting pyrazinone derivatives
TW200531688A (en)	2005-10-01	Novel pentafluorosulfanyl compounds, their manufacture and use as pharmaceutical agents
MX2021014830A (es)	2022-01-18	Conjugados de compuestos que comprenden nitrogeno heteroaromatico donador de pares de electrones pi.
WO2008004100A3 (en)	2011-06-16	Therapeutic compounds
SI1858861T1 (sl)	2010-10-29	2-(4-cianofenil)-6-hidroksilaminopirimidini, ki inhibirajo HIV
PH12019500327A1 (en)	2019-11-11	Indazole compounds for use in tendon and/or ligament injuries
MX2020009711A (es)	2020-10-07	Combinacion de quinolin-4-carboxamidas y derivados de benzonaftiridina como combinacion de farmacos antipaludicos.
UA81654C2 (ru)	2008-01-25	Пиримидины и триазины, которые ингибируют репликацию вич
MX2009004187A (es)	2009-04-30	Derivados de heterociclil piridil sulfonamida, su manufactura y uso como agentes farmaceuticos.